Nexalin Technology (NXL) Current Deferred Revenue (2021)
Nexalin Technology (NXL) posted quarterly Current Deferred Revenue of $130000.0 for Q4 2021.
Nexalin Technology (NXL) Current Deferred Revenue (2021) Analysis & Trends
Nexalin Technology's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $130000.0 for Q4 2021.
- In Q4 2021, Current Deferred Revenue changed N/A year-over-year to $130000.0; the TTM figure through Dec 2021 stood at $130000.0 (changed N/A YoY), while the FY2021 annual figure was $130000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2021 stood at $130000.0.
- The five-year high for Current Deferred Revenue was $130000.0 in Q4 2021, with the low at $130000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 130,000.00 |